NIKKEI 225
32,678.62 +276.21 (+0.85%) HANG SENG
17,729.29 -328.16 (-1.82%) CRUDE OIL
90.06 +0.03 (+0.03%) GOLD FUTURES
1,935.40 -10.20 (-0.52%) DOW
33,926.82 -37.02 (-0.11%) Bitcoin GBP
21,594.82 -170.70 (-0.78%)
NVO Oct 2023 80.000 put
| Previous close | 0.3800 |
| Open | 0.4000 |
| Bid | 0.3000 |
| Ask | 0.4000 |
| Strike | 80.00 |
| Expiry date | 2023-10-20 |
| Day's range | 0.3600 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.78k |
Globe NewswireValo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence
Collaboration will apply Valo’s Opal Computational Platform™ and real-world patient dataset to enable the discovery and development of novel cardiometabolic drug programmes Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular diseases discovered and developed by Valo using the Opal Computational Platform™ Valo will receive an upfront payment and a potential near-term milestone payment, totalling 60 million US dollars, and is eligible to receive milestone payments f
Motley FoolWhich High-Profile Stock-Split Stock Is the Cheapest? Get Ready to Be Shocked...
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's one clear-cut stock-split stock that's notably cheaper than the rest.
BloombergObesity Drug Market Set to Hit $100 Billion by 2035, BMO Says
(Bloomberg) -- The global market for novel weight-loss drugs like Novo Nordisk A/S’s Ozempic and Wegovy is poised to reach $100 billion by 2035 as patients start to understand the efficacy of the medications.Most Read from BloombergChinese Gold Buying Is Driving a Paradigm Shift in BullionStocks Flash Recession Warning as Trouble Spreads to IndustrialsWells Fargo Preps for Wealth Battle After $1 Billion TurnaroundBond Market Faces Quandary After Fed Signals It’s Almost DoneUS to Keep a Distance
